BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Norak Biosciences, Inc. And Curis, Inc. (CRIS) Sign Research Agreement


10/19/2005 5:11:48 PM

RESEARCH TRIANGLE PARK, N.C., Oct. 20 /PRNewswire/ -- Norak Biosciences, Inc. announced today the signing of a research agreement with Curis, Inc. to investigate the use of its Transfluor(R) technology with a novel class of receptors of interest to Curis. Under terms of the agreement, Norak will utilize its proprietary Transfluor Technology, related intellectual property and scientific expertise to developed Transfluor cell lines expressing Curis' receptors. Financial details of the agreement are not disclosed.

"We are pleased to partner with Curis to develop assays for an important receptor class," stated Dr. Roger D. Blevins, Norak's President and CEO. "To date, we have partnered Transfluor(R) with 10 pharmaceutical, biotechnology or major research institutions and it is gratifying to see the interest in our technology by Curis and others in the pursuit of innovative medicines."

For near-term growth and revenue, Norak is offering access to its technologies to the drug discovery industry via licensing and screening collaborations. For long-term growth and value, Norak has internal GPCR drug development programs based on novel GPCR targets and compounds.

Norak's Transfluor technology is a patented, universal GPCR drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against GPCR targets, whether known or orphan. Transfluor was licensed in 1999 by Norak from technology developed at Duke University Medical Center and represents the combined research into GPCR signaling pathways over several decades by Norak's scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak.

About Norak:

Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private venture-capital backed biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.

For more information about Norak Biosciences, Inc., please visit the Company's website at http://www.norakbio.com/ .

Contact: Terry E. Willard Executive Vice President Norak Biosciences, Inc. 7030 Kit Creek Road Morrisville, NC 27560 Phone: 919-248-8000 ext. 8804 Fax: 919-248-8033 twillard@norakbio.com

Norak Biosciences, Inc.

CONTACT: Terry E. Willard, Executive Vice President of NorakBiosciences, Inc., +1-919-248-8000 ext. 8804, or Fax, +1-919-248-8033, ortwillard@norakbio.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES